General Information |
Business: |
We are an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia is our lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. We expect to announce data from our proof-of-concept study of Canalevia for general acute watery diarrhea in dogs in the fourth quarter of 2014. We also expect to initiate filing of a rolling new animal drug application, or NADA, for Canalevia for chemotherapy-induced diarrhea, or CID, in dogs, by the end of 2014. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. A human-specific formulation of crofelemer, Fulyzaq, was approved by the U.S. Food and Drug Administration, or FDA, in 2012 for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. |
|
Industry: |
PHARMACEUTICAL PREPARATIONS |
|
Employees: |
17 |
Founded: |
2013 |
|
Contact Information |
Address: |
185 Berry Street, Suite 1300, San Francisco, CA 94107, US |
|
|
|
|
Financial Information |
|
Revenues: |
$ 0.0 mil (last 12 months) |
|
Net Income: |
$ -9.3 mil (last 12 months) |
|
IPO Profile |
|
|
|
|